文献速递肝病消化道肿瘤与早癌

脂肪性肝炎型肝细胞癌的多组学特征与诊疗模型

Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma.
PubMed 文献 · Gut · 2026-09-22

本研究整合156例患者的临床与多组学数据,刻画脂肪性肝炎型肝细胞癌(SH-HCC)的分子特征并构建无创诊断模型。SH-HCC指数可区分SH-HCC与传统HCC,基于12种脂质的诊断模型在独立队列中AUC达0.909,血清蛋白组模型在测试队列中AUC为0.828,FABP4基因缺失可抑制小鼠肿瘤生长并增强PD-1阻断疗效。

要点

  • SH-HCC指数可可靠区分SH-HCC与传统HCC。
  • 基于12种脂质的诊断模型在独立队列中AUC为0.909。
  • FABP4基因缺失抑制小鼠肿瘤生长并增强PD-1阻断疗效。

核心结论

  • 本研究首次对SH-HCC进行多组学刻画,提出SH-HCC指数和无创诊断模型,并提示FABP4为潜在治疗靶点。

研究设计与样本

  • 整合156例患者的临床与多组学数据,包括RNA-seq(n=69)、空间转录组(n=36)、空间代谢组(n=6)、脂质组(n=125)和血清蛋白组(n=152)。
  • FABP4在Sleeping Beauty诱导的HCC小鼠模型中进行功能验证。

主要发现

  • SH-HCC指数可可靠区分SH-HCC与传统HCC。
  • 药物反应分析提示SH-HCC对索拉非尼和免疫治疗方案的反应性可能降低,而经动脉化疗栓塞可能仍为有效选择。
  • 空间转录组显示免疫细胞浸润增加、免疫屏障增强及肿瘤-免疫细胞通讯减少。
  • SH-HCC以富脂表型为特征,基于12种脂质的诊断模型在独立队列中AUC=0.909,血清蛋白组模型在测试队列中AUC=0.828。
  • FABP4基因缺失抑制小鼠肿瘤生长、重塑肿瘤免疫微环境并增强PD-1阻断反应。

关键数值与推荐

  • 基于12种脂质的诊断模型在独立队列中AUC=0.909。
  • 血清蛋白组模型在测试队列中AUC=0.828。

临床怎么用

  • SH-HCC指数和基于脂质或血清蛋白组的无创模型可用于SH-HCC的鉴别诊断。
  • SH-HCC患者对索拉非尼和免疫治疗的反应性可能降低,经动脉化疗栓塞可能仍有效。
  • FABP4可能作为SH-HCC的潜在治疗靶点,其缺失可增强PD-1阻断疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Steatohepatitic hepatocellular carcinoma (SH-HCC) is a distinct subtype of hepatocellular carcinoma with poorly defined molecular features and limited diagnostic and therapeutic strategies. OBJECTIVE: This study aimed to delineate its multi-omics landscape, develop non-invasive diagnostic tools and identify actionable therapeutic targets. DESIGN: We integrated multimodal clinical and omics datasets from an overall cohort of 156 patients, including RNA-seq (n=69), spatial transcriptomics (n=36), spatial metabolomics (n=6), lipidomics (n=125) and serum proteomics (n=152), for comprehensive molecular profiling and diagnostic model construction. FABP4 was functionally validated in Sleeping Beauty-induced HCC mouse models. RESULTS: An SH-HCC index was established to reliably differentiate SH-HCC from conventional HCC. Drug response analysis suggested a potential reduction in responsiveness to sorafenib and immunotherapy-based regimens in SH-HCC, whereas transarterial chemoembolisation may remain an effective therapeutic option. Spatial transcriptomics revealed increased immune cell infiltration, a reinforced immune barrier and reduced tumour-immune cell communication. SH-HCC is characterised by a lipid-rich phenotype, and a diagnostic model based on 12 lipid species showed good performance in an independent cohort (area under the curve (AUC)=0.909). Serum proteomic model demonstrated good performance in the test cohort (AUC=0.828). Importantly, our preliminary findings suggest a potential therapeutic role for FABP4, as its genetic deletion suppressed tumour growth, reshaped the tumour immune microenvironment and enhanced the response to PD-1 blockade. CONCLUSION: This study provides the first multi-omics characterisation of SH-HCC, highlighting the SH-HCC index and non-invasive diagnostic models, with FABP4 as a potential target.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhang L, Chen C, Xu Y, et al. Integrative multi-omics landscape and diagnostic-therapeutic modelling of steatohepatitic hepatocellular carcinoma. Gut. 2026. PMID: 42772859. doi:10.1136/gutjnl-2026-339304

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。